Physician profile
James Cumella
NPI 1093725665
$2,191.86
in general payments reported to CMS, 2019-2025
13 companies · $991 in 2025
The $991 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.70 · 2021: $13.91 · 2022: $86.87 · 2023: $348 · 2024: $701 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.44 |
| Education | $282.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $609.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $307.82 | 2019-2025 | Fasenra, Airsupra |
| Sanofi-Aventis U.S. LLC | $282.94 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $147.28 | 2025 | Dupixent |
| Pfizer INC. | $142.86 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $134.61 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $127.76 | 2019-2024 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2023 | Glassia |
| Optinose US, INC. | $124.99 | 2024 | |
| Genentech USA, INC. | $119.36 | 2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.13 | 2022 | |
| Grifols USA, LLC | $20.78 | 2022 | |
| Biocryst US Sales Co., LLC | $14.05 | 2025 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cumella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.